Non-small Cell Lung Cancer (NSCLC) Disease Forecast & Market Analysis to 2035 - Sales of PD-1/PD-L1 Targeted Immunotherapies in NSCLC are Forecast to Grow to $18.3Bn by 2026 - ResearchAndMarkets.com

DUBLIN--()--The "Non-small Cell Lung Cancer (NSCLC) Disease Forecast & Market Analysis to 2035" report has been added to ResearchAndMarkets.com's offering.

Market Snapshot

  • Sales of PD-1/PD-L1 targeted immunotherapies in NSCLC are forecast to grow to $18.3bn by 2026.
  • The treatment of NSCLC continues to be guided by the presence of genetic aberrations and variations in disease histology.
  • Despite decreasing and plateauing incidence rates, incident cases will continue to grow due to aging populations.
  • Keytruda's dominance of the first-line setting positions it to be the leading immunotherapy in NSCLC.
  • Pipeline therapy developers will seek approvals in niche indications to differentiate in this increasingly crowded space.

Disease Overview

Lung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancer (NSCLC), with the exact proportion depending on the country in question. The main types of NSCLC are squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. NSCLC presents significant public health problems for nearly every country, largely due to the fact that diagnosis generally happens in the advanced stages, and there is a high death rate associated with the disease.

Key Topics Covered

FORECAST: NON-SMALL CELL LUNG CANCER

Overview

Recent Forecast Updates

Market Dynamics

Forecast And Future Trends

Market Definition And Methodology

Primary Research Methodology

Bibliography

Product Profile: Abraxane

Product Profile: Alecensa

Product Profile: Alimta

Product Profile: Alunbrig

Product Profile: Avastin

Product Profile (Late Stage): Bavencio

Product Profile: Cyramza

Product Profile: Gilotrif

Product Profile: Imfinzi

Product Profile: Iressa

Product Profile: Keytruda

Product Profile: Mekinist

Product Profile: Opdivo

Product Profile: Portrazza

Product Profile: Tafinlar

Product Profile: Tagrisso

Product Profile: Tarceva

Product Profile: Tecentriq

Product Profile: Vargatef

Product Profile: Xalkori

Product Profile: Zykadia

Product Profile (Late Stage): Ca

Product Profile (Late Stage): Entrectinib

Product Profile (Late Stage): Lorlatinib

Product Profile (Late Stage): Seribantumab

TREATMENT: NON-SMALL CELL LUNG CANCER

Overview

Primary Research Methodology

Disease Definition And Diagnosis

Patient Segmentation

Current Treatment Options

Treatment Trends

Prescribing Trends: Early-Stage Nsclc, All Subtypes

Prescribing Trends: Non-Squamous Egfr Mutation-Positive, Advanced And Metastatic

Prescribing Trends: Non-Squamous Alk Rearrangement-Positive, Advanced And Metastatic

Prescribing Trends: All Other Non-Squamous, Advanced And Metastatic

Prescribing Trends: Squamous, Advanced And Metastatic

EPIDEMIOLOGY: NON-SMALL CELL LUNG CANCER

Overview

Disease Background

Methodology

Forecast

Bibliography

MARKETED DRUGS: NON-SMALL CELL LUNG CANCER (NSCLC)

Overview

Product Overview

Product Profile: Abraxane

Product Profile: Alecensa

Product Profile: Alimta

Product Profile: Alunbrig

Product Profile: Avastin

Product Profile: Cyramza

Product Profile: Gilotrif

Product Profile: Imfinzi

Product Profile: Iressa

Product Profile: Keytruda

Product Profile: Mekinist

Product Profile: Opdivo

Product Profile: Portrazza

Product Profile: Tafinlar

Product Profile: Tagrisso

Product Profile: Tarceva

Product Profile: Tecentriq

Product Profile: Vargatef

Product Profile: Xalkori

Product Profile: Zykadia

PIPELINE: NON-SMALL CELL LUNG CANCER

Overview

Clinical Pipeline Overview

Additional Pharma Intelligence Pipeline Resources

Product Profile (Late Stage): Bavencio

Product Profile (Late Stage): Capmatinib

Product Profile (Late Stage): Cemiplimab

Product Profile (Late Stage): Dacomitinib

Product Profile (Late Stage): Ensartinib

Product Profile (Late Stage): Entrectinib

Product Profile (Late Stage): Lorlatinib

Product Profile (Late Stage): Seribantumab

For more information about this report visit https://www.researchandmarkets.com/r/kwrcvi

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lung Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lung Cancer Drugs